Market Overview

UPDATE: Piper Jaffray Initiates Inovio Pharmaceuticals at Overweight on DNA Vaccine Outlook

Share:
Related INO
io Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV
Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV

Piper Jaffray initiated coverage on Inovio Pharmaceuticals (NYSE: INO) with an Overweight rating and a $1.00 price target.

Piper Jaffray noted, "Inovio is developing a novel DNA-based vaccine platform, utilizing proprietary electroporation technology to create robust immune responses. Inovio's vaccines have demonstrated provocative immune responses in early studies against a multiple non-viral oncology targets (prostate, leukemia, breast, lung), as well as several infectious diseases HIV, HCV, HPV, and the flu. Based on earlier validation for producing uncommonly robust T-Cell responses, we are optimistic for the data expected in 4Q13, but note multiple Phase II catalysts expected this year in HCV and leukemia."

Inovio Pharmaceuticals closed at $0.67 on Thursday.

Latest Ratings for INO

DateFirmActionFromTo
Jul 2014Aegis CapitalUpgradesHoldBuy
May 2014Stifel NicolausInitiates Coverage onBuy
Nov 2013Aegis CapitalReiteratesHold

View More Analyst Ratings for INO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (INO)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content